Relmada Therapeutics

SEC Filing Alert for Relmada Therapeutics, Inc.

Relmada Therapeutics sent this email to their subscribers on September 12, 2024.

The following documents have been filed with the SEC:

SEC Filing Alert

4: Statement of changes in beneficial ownership of securities

If you have any questions, or would like to contact Investor Relations, please reply to this email.

Text-only version of this email

Relmada Therapeutics, Inc. Investor Relations Relmada THERAPEUTICS The following documents have been filed with the SEC: SEC FILING ALERT 4: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES HTML PDF If you have any questions, or would like to contact Investor Relations, please reply to this email. Relmada Therapeutics, Inc. 880 Third Avenue, 12th Floor, New York, NY 10022 United States of America Change Your

Show all

The Latest Emails Sent By Relmada Therapeutics

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

Relmada Therapeutics to discontinue the Reliance II and Relight Phase 3 studies of REL-1017

Relmada Therapeutics to discontinue the Reliance II and Relight Phase 3 studies of REL-1017

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

More Emails, Deals & Coupons From Relmada Therapeutics

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

SEC Filing Alert for Relmada Therapeutics, Inc.

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update